Glial Fibrillary Acidic Protein (GFAP)
Theme of SensUs 2023
Traumatic brain injury with GFAP as a biomarker
TBI is a silent epidemic with an estimated 64–74 million new cases each year. The impairments suffered by many TBI patients, such as memory loss, cognitive dysfunction, or behavioral disturbance, are often not visible. One of the problems is that the severity is difficult to judge at the moment of the injury, while it is very important for the required treatment. Therefore, tools are needed for the rapid diagnosis of the severity of TBI, so that appropriate treatment will be given and the lives of patients can be improved.